Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Antimetabolites"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 49
Tytuł:
Pilot Study to Predict Pharmacokinetics of a Therapeutic Gemcitabine Dose From a Microdose.
Autorzy:
Van Nuland M; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Rosing H; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Thijssen B; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Burgers JA; Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Huitema ADR; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Clinical Pharmacy University Medical Center Utrecht, Utrecht University, the Netherlands.
Marchetti S; Division of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Schellens JHM; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.
Beijnen JH; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.
Pokaż więcej
Źródło:
Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2020 Nov; Vol. 9 (8), pp. 929-937. Date of Electronic Publication: 2020 Jan 22.
Typ publikacji:
Clinical Trial; Comparative Study; Journal Article
MeSH Terms:
Dose-Response Relationship, Drug*
Antimetabolites, Antineoplastic/*pharmacokinetics
Chromatography, Liquid/*methods
Deoxycytidine/*analogs & derivatives
Mass Spectrometry/*instrumentation
Administration, Intravenous ; Aged ; Antimetabolites, Antineoplastic/administration & dosage ; Antimetabolites, Antineoplastic/blood ; Antimetabolites, Antineoplastic/therapeutic use ; Area Under Curve ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Deoxycytidine/administration & dosage ; Deoxycytidine/blood ; Deoxycytidine/pharmacokinetics ; Deoxycytidine/therapeutic use ; Female ; Humans ; Male ; Mesothelioma/drug therapy ; Middle Aged ; Pilot Projects ; Predictive Value of Tests ; Prospective Studies ; Thymoma/drug therapy ; Gemcitabine
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis.
Autorzy:
Jacobs BAW; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Deenen MJ; Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, The Netherlands.; Department of Clinical Pharmacology and Toxicology, Leiden University Medical Centre, Leiden, The Netherlands.
Joerger M; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Rosing H; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
de Vries N; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Meulendijks D; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Dutch Medicines Evaluation Board, Utrecht, The Netherlands.
Cats A; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Beijnen JH; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Pharmaco-epidemiology & Clinical Pharmacology, Science Faculty, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
Schellens JHM; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Pharmaco-epidemiology & Clinical Pharmacology, Science Faculty, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
Huitema ADR; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2019 Dec; Vol. 8 (12), pp. 940-950. Date of Electronic Publication: 2019 Nov 20.
Typ publikacji:
Journal Article
MeSH Terms:
Antimetabolites, Antineoplastic/*pharmacokinetics
Capecitabine/*pharmacokinetics
Dihydrouracil Dehydrogenase (NADP)/*genetics
Neoplasms/*drug therapy
Adult ; Aged ; Antimetabolites, Antineoplastic/administration & dosage ; Capecitabine/administration & dosage ; Capecitabine/chemistry ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/pharmacokinetics ; Female ; Floxuridine/pharmacokinetics ; Gastrectomy ; Humans ; Male ; Middle Aged ; Neoplasms/blood ; Neoplasms/genetics ; Pharmacogenomic Variants ; Prodrugs
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nab-paclitaxel in pancreatic cancer.
Autorzy:
Zhang Z; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Shanghai Pancreatic Cancer Institute, Shanghai, China.; Pancreatic Cancer Institute, Fudan University, Shanghai, China.
Ji S; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Shanghai Pancreatic Cancer Institute, Shanghai, China.; Pancreatic Cancer Institute, Fudan University, Shanghai, China.
Hu Q; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Shanghai Pancreatic Cancer Institute, Shanghai, China.; Pancreatic Cancer Institute, Fudan University, Shanghai, China.
Zhuo Q; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Shanghai Pancreatic Cancer Institute, Shanghai, China.; Pancreatic Cancer Institute, Fudan University, Shanghai, China.
Liu W; Department of Radiology, Fudan University Shanghai Cancer Center, Shanghai, China.
Xu W; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Shanghai Pancreatic Cancer Institute, Shanghai, China.; Pancreatic Cancer Institute, Fudan University, Shanghai, China.
Liu W; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Shanghai Pancreatic Cancer Institute, Shanghai, China.; Pancreatic Cancer Institute, Fudan University, Shanghai, China.
Liu M; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Shanghai Pancreatic Cancer Institute, Shanghai, China.; Pancreatic Cancer Institute, Fudan University, Shanghai, China.
Ye Z; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Shanghai Pancreatic Cancer Institute, Shanghai, China.; Pancreatic Cancer Institute, Fudan University, Shanghai, China.
Fan G; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Shanghai Pancreatic Cancer Institute, Shanghai, China.; Pancreatic Cancer Institute, Fudan University, Shanghai, China.
Xu X; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Shanghai Pancreatic Cancer Institute, Shanghai, China.; Pancreatic Cancer Institute, Fudan University, Shanghai, China.
Yu X; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Shanghai Pancreatic Cancer Institute, Shanghai, China.; Pancreatic Cancer Institute, Fudan University, Shanghai, China.
Qin Y; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Shanghai Pancreatic Cancer Institute, Shanghai, China.; Pancreatic Cancer Institute, Fudan University, Shanghai, China.
Pokaż więcej
Źródło:
Clinical and translational medicine [Clin Transl Med] 2021 Aug; Vol. 11 (8), pp. e398.
Typ publikacji:
Case Reports; Letter; Research Support, Non-U.S. Gov't
MeSH Terms:
Adenocarcinoma/*drug therapy
Antimetabolites, Antineoplastic/*administration & dosage
Antineoplastic Agents, Immunological/*therapeutic use
Bevacizumab/*therapeutic use
Carcinoma, Pancreatic Ductal/*drug therapy
Pancreatic Neoplasms/*drug therapy
Albumins/administration & dosage ; Deoxycytidine/administration & dosage ; Deoxycytidine/analogs & derivatives ; Fatal Outcome ; Humans ; Male ; Middle Aged ; Paclitaxel/administration & dosage ; Treatment Outcome ; Gemcitabine
Raport
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
A unique breast involvement detected by MRI-DWIBS in T cell acute lymphoblastic leukemia.
Autorzy:
Katagiri S; Department of Hematology, Tokyo Medical University, Tokyo, Japan.
Azuma K; Institute of Medical Science, Tokyo Medical University, Tokyo, Japan.
Akahane D; Department of Hematology, Tokyo Medical University, Tokyo, Japan.
Saito K; Department of Radiology, Tokyo Medical University, Tokyo, Japan.
Ohyashiki K; Department of Hematology, Tokyo Medical University, Tokyo, Japan.
Pokaż więcej
Źródło:
The breast journal [Breast J] 2019 Nov; Vol. 25 (6), pp. 1276-1277. Date of Electronic Publication: 2019 Jul 12.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Breast Neoplasms*/drug therapy
Breast Neoplasms*/pathology
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma*/drug therapy
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma*/pathology
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Asparaginase/*administration & dosage
Cytarabine/*administration & dosage
Diffusion Magnetic Resonance Imaging/*methods
Drug Monitoring/*methods
Methotrexate/*administration & dosage
Whole Body Imaging/*methods
Antimetabolites, Antineoplastic/administration & dosage ; Bone Marrow Examination/methods ; Cyclophosphamide/administration & dosage ; Dexamethasone/administration & dosage ; Doxorubicin/administration & dosage ; Female ; Humans ; Middle Aged ; Neoplasm Staging ; Treatment Outcome ; Vincristine/administration & dosage
SCR Protocol:
CVAD protocol
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
5-HT₃ receptor antagonists ameliorate 5-fluorouracil-induced intestinal mucositis by suppression of apoptosis in murine intestinal crypt cells.
Autorzy:
Yasuda M; Division of Pathological Sciences, Department of Pharmacology and Experimental Therapeutics, Kyoto Pharmaceutical University, Kyoto, Japan.
Kato S
Yamanaka N
Iimori M
Matsumoto K
Utsumi D
Kitahara Y
Amagase K
Horie S
Takeuchi K
Pokaż więcej
Źródło:
British journal of pharmacology [Br J Pharmacol] 2013 Mar; Vol. 168 (6), pp. 1388-400.
Typ publikacji:
Journal Article
MeSH Terms:
Antimetabolites, Antineoplastic/*adverse effects
Apoptosis/*drug effects
Fluorouracil/*adverse effects
Immunosuppressive Agents/*adverse effects
Intestinal Mucosa/*drug effects
Mucositis/*prevention & control
Serotonin 5-HT3 Receptor Antagonists/*therapeutic use
Animals ; Antimetabolites, Antineoplastic/therapeutic use ; Apoptosis Regulatory Proteins/antagonists & inhibitors ; Apoptosis Regulatory Proteins/genetics ; Apoptosis Regulatory Proteins/metabolism ; Benzimidazoles/administration & dosage ; Benzimidazoles/adverse effects ; Benzimidazoles/therapeutic use ; Colonic Neoplasms/drug therapy ; Cytokines/genetics ; Cytokines/metabolism ; Diarrhea/etiology ; Diarrhea/prevention & control ; Dose-Response Relationship, Drug ; Drug Interactions ; Fluorouracil/antagonists & inhibitors ; Fluorouracil/therapeutic use ; Gastrointestinal Agents/administration & dosage ; Gastrointestinal Agents/therapeutic use ; Gene Expression Regulation/drug effects ; Immunosuppressive Agents/antagonists & inhibitors ; Immunosuppressive Agents/therapeutic use ; Intestinal Mucosa/immunology ; Intestinal Mucosa/metabolism ; Intestinal Mucosa/pathology ; Male ; Mice ; Mice, Inbred C57BL ; Mucositis/chemically induced ; Mucositis/metabolism ; Mucositis/pathology ; Ondansetron/adverse effects ; Ondansetron/therapeutic use ; Serotonin 5-HT3 Receptor Agonists/adverse effects ; Serotonin 5-HT3 Receptor Agonists/therapeutic use ; Serotonin 5-HT3 Receptor Antagonists/administration & dosage ; Serotonin 5-HT3 Receptor Antagonists/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Gemcitabine-associated livedoid thrombotic microangiopathy with associated sclerema neonatorum-like microscopic changes.
Autorzy:
Mir-Bonafé JM; Department of Dermatology, University Hospital of Salamanca, Salamanca, Spain. />Román-Curto C
Santos-Briz A
Cañueto J
Fernández-López E
Unamuno P
Pokaż więcej
Źródło:
Journal of cutaneous pathology [J Cutan Pathol] 2012 Jul; Vol. 39 (7), pp. 707-11. Date of Electronic Publication: 2012 May 22.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Leukocytes*/metabolism
Leukocytes*/pathology
Thrombotic Microangiopathies*/chemically induced
Thrombotic Microangiopathies*/metabolism
Thrombotic Microangiopathies*/pathology
Antimetabolites, Antineoplastic/*adverse effects
Deoxycytidine/*analogs & derivatives
Fibrin/*metabolism
Skin/*pathology
Antimetabolites, Antineoplastic/administration & dosage ; Deoxycytidine/administration & dosage ; Deoxycytidine/adverse effects ; Humans ; Male ; Middle Aged ; Gemcitabine
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
DNA mismatch repair (MMR)-dependent 5-fluorouracil cytotoxicity and the potential for new therapeutic targets.
Autorzy:
Li LS; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Morales JC
Veigl M
Sedwick D
Greer S
Meyers M
Wagner M
Fishel R
Boothman DA
Pokaż więcej
Źródło:
British journal of pharmacology [Br J Pharmacol] 2009 Oct; Vol. 158 (3), pp. 679-92. Date of Electronic Publication: 2009 Sep 23.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
MeSH Terms:
DNA Mismatch Repair*
Antimetabolites, Antineoplastic/*pharmacology
Fluorouracil/*pharmacology
Neoplasms/*drug therapy
Antimetabolites, Antineoplastic/metabolism ; Antimetabolites, Antineoplastic/therapeutic use ; Cell Line, Tumor ; Fluorouracil/metabolism ; Fluorouracil/therapeutic use ; Humans ; Models, Biological ; Neoplasms/genetics ; Neoplasms/metabolism ; Signal Transduction
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Cytosine arabinoside induces ectoderm and inhibits mesoderm expression in human embryonic stem cells during multilineage differentiation.
Autorzy:
Jagtap S; Center of Physiology and Pathophysiology, Institute of Neurophysiology, Cologne, Germany.
Meganathan K
Gaspar J
Wagh V
Winkler J
Hescheler J
Sachinidis A
Pokaż więcej
Źródło:
British journal of pharmacology [Br J Pharmacol] 2011 Apr; Vol. 162 (8), pp. 1743-56.
Typ publikacji:
Journal Article
MeSH Terms:
Antimetabolites, Antineoplastic/*toxicity
Cell Differentiation/*drug effects
Cytarabine/*toxicity
Embryonic Stem Cells/*drug effects
Animal Testing Alternatives/methods ; Animals ; Antimetabolites, Antineoplastic/administration & dosage ; Cytarabine/administration & dosage ; Ectoderm/drug effects ; Ectoderm/metabolism ; Embryonic Stem Cells/metabolism ; Gene Expression Profiling ; Humans ; Mesoderm/drug effects ; Mesoderm/metabolism ; Mice ; Oligonucleotide Array Sequence Analysis ; Time Factors
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Thiopurine metabolism monitoring: implications in inflammatory bowel diseases.
Autorzy:
Dewit O; St. Luc University Hospital, Catholic University of Louvain Brussels, Brussels, Belgium CHU Saint-Etienne, Saint-Etienne, France. />Starkel P
Roblin X
Pokaż więcej
Źródło:
European journal of clinical investigation [Eur J Clin Invest] 2010 Nov; Vol. 40 (11), pp. 1037-47. Date of Electronic Publication: 2010 Aug 19.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Antimetabolites/*adverse effects
Gastrointestinal Agents/*adverse effects
Inflammatory Bowel Diseases/*drug therapy
Methyltransferases/*metabolism
Purines/*adverse effects
Thionucleotides/*adverse effects
Antimetabolites/pharmacology ; Dose-Response Relationship, Drug ; Gastrointestinal Agents/pharmacology ; Humans ; Inflammatory Bowel Diseases/genetics ; Methyltransferases/genetics ; Purines/pharmacology ; Thionucleotides/pharmacology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Effects of the cortisol synthesis inhibitor metyrapone on the response to carbon dioxide challenge in panic disorder.
Autorzy:
Belgorodsky A; Division of Psychiatry, Ben Gurion University of the Negev, Beer-sheba, Israel.
Knyazhansky L
Loewenthal U
Arbelle J
Cohen H
Benjamin J
Pokaż więcej
Źródło:
Depression and anxiety [Depress Anxiety] 2005; Vol. 21 (3), pp. 143-8.
Typ publikacji:
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carbon Dioxide*/administration & dosage
Antimetabolites/*pharmacology
Hydrocortisone/*metabolism
Metyrapone/*pharmacology
Panic Disorder/*diagnosis
Administration, Inhalation ; Adrenocorticotropic Hormone/blood ; Antimetabolites/administration & dosage ; Corticotropin-Releasing Hormone/physiology ; Diagnostic and Statistical Manual of Mental Disorders ; Humans ; Hydrocortisone/biosynthesis ; Hydrocortisone/blood ; Hypothalamo-Hypophyseal System/drug effects ; Metyrapone/administration & dosage ; Panic Disorder/physiopathology ; Pituitary-Adrenal System/drug effects ; Surveys and Questionnaires
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Time course of bleomycin-induced lung fibrosis.
Autorzy:
Izbicki G; Lung Cellular & Molecular Biology Laboratory - Institute of Pulmonology, Hadassah University Hospital and Hebrew University-Hadassah Medical School, Jerusalem, Israel.
Segel MJ
Christensen TG
Conner MW
Breuer R
Pokaż więcej
Źródło:
International journal of experimental pathology [Int J Exp Pathol] 2002 Jun; Vol. 83 (3), pp. 111-9.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antimetabolites, Antineoplastic*
Bleomycin*
Image Processing, Computer-Assisted*
Models, Animal*
Lung/*pathology
Pulmonary Fibrosis/*pathology
Animals ; Bronchoalveolar Lavage Fluid/chemistry ; Bronchoalveolar Lavage Fluid/cytology ; Cell Count ; Hydroxyproline/analysis ; Instillation, Drug ; Male ; Mice ; Mice, Inbred C57BL ; Time Factors
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
5-fluorouracil causes endothelial cell senescence: potential protective role of glucagon-like peptide 1.
Autorzy:
Altieri P; Laboratory of Cardiovascular Biology, Department of Internal Medicine, University of Genova, Genova, Italy.
Murialdo R; Oncology Unit, IRCCS AOU San Martino-IST, Genova, Italy.
Barisione C; Laboratory of Cardiovascular Biology, Department of Internal Medicine, University of Genova, Genova, Italy.
Lazzarini E; Laboratory of Cardiovascular Biology, Department of Internal Medicine, University of Genova, Genova, Italy.
Garibaldi S; Laboratory of Cardiovascular Biology, Department of Internal Medicine, University of Genova, Genova, Italy.
Fabbi P; Laboratory of Cardiovascular Biology, Department of Internal Medicine, University of Genova, Genova, Italy.
Ruggeri C; Laboratory of Cardiovascular Biology, Department of Internal Medicine, University of Genova, Genova, Italy.
Borile S; Cardiovascular Disease Unit, IRCCS AOU San Martino-IST, Genova, Italy.
Carbone F; First Clinic of Internal Medicine, IRCCS AOU San Martino - IST, Genova, Italy.; Department of Internal Medicine, University of Genova, Genova, Italy.
Armirotti A; Drug Discovery and Development Department, Italian Institute of Technology (IIT), Genova, Italy.
Canepa M; Laboratory of Cardiovascular Biology, Department of Internal Medicine, University of Genova, Genova, Italy.; Cardiovascular Disease Unit, IRCCS AOU San Martino-IST, Genova, Italy.
Ballestrero A; Oncology Unit, IRCCS AOU San Martino-IST, Genova, Italy.
Brunelli C; Laboratory of Cardiovascular Biology, Department of Internal Medicine, University of Genova, Genova, Italy.; Cardiovascular Disease Unit, IRCCS AOU San Martino-IST, Genova, Italy.
Montecucco F; First Clinic of Internal Medicine, IRCCS AOU San Martino - IST, Genova, Italy.; Department of Internal Medicine, University of Genova, Genova, Italy.; Centre of Excellence for Biomedical Research (CEBR), University of Genova, Genova, Italy.
Ameri P; Laboratory of Cardiovascular Biology, Department of Internal Medicine, University of Genova, Genova, Italy.; Cardiovascular Disease Unit, IRCCS AOU San Martino-IST, Genova, Italy.
Spallarossa P; Laboratory of Cardiovascular Biology, Department of Internal Medicine, University of Genova, Genova, Italy.; Cardiovascular Disease Unit, IRCCS AOU San Martino-IST, Genova, Italy.
Pokaż więcej
Źródło:
British journal of pharmacology [Br J Pharmacol] 2017 Nov; Vol. 174 (21), pp. 3713-3726. Date of Electronic Publication: 2017 Feb 22.
Typ publikacji:
Journal Article
MeSH Terms:
Capecitabine/*administration & dosage
Cellular Senescence/*drug effects
Endothelial Cells/*drug effects
Fluorouracil/*toxicity
Glucagon-Like Peptide 1/*administration & dosage
Aged ; Antimetabolites, Antineoplastic/toxicity ; Blotting, Western ; Cell Line ; Endothelial Cells/pathology ; Enzyme-Linked Immunosorbent Assay ; Female ; Glucagon-Like Peptide 1/pharmacology ; Humans ; Male ; Reverse Transcriptase Polymerase Chain Reaction
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Gemcitabine Induced Cutaneous Collagenous Vasculopathy in a Breast Cancer Patient.
Autorzy:
Leone JP; Division of Hematology and Oncology, University of Iowa Holden Comprehensive Cancer Center, Iowa City, Iowa.
Pokaż więcej
Źródło:
The breast journal [Breast J] 2016 Sep; Vol. 22 (5), pp. 580. Date of Electronic Publication: 2016 Jun 27.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Antimetabolites, Antineoplastic/*adverse effects
Breast Neoplasms/*drug therapy
Deoxycytidine/*analogs & derivatives
Skin Diseases, Vascular/*chemically induced
Aged ; Deoxycytidine/adverse effects ; Female ; Humans ; Skin Diseases, Vascular/pathology ; Telangiectasis/chemically induced ; Telangiectasis/pathology ; Gemcitabine
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
RANDOMIZED TRIAL OF D-CYCLOSERINE ENHANCEMENT OF COGNITIVE-BEHAVIORAL THERAPY FOR PANIC DISORDER.
Autorzy:
Otto MW; Department of Psychological and Brain Sciences, Boston University, Boston, Massachusetts.
Pollack MH; Department of Psychiatry, Rush University Medical Center, Chicago, Illinois.
Dowd SM; Department of Psychiatry, Rush University Medical Center, Chicago, Illinois.
Hofmann SG; Department of Psychological and Brain Sciences, Boston University, Boston, Massachusetts.
Pearlson G; Institute of Living and Yale University School of Medicine, Hartford, Connecticut.
Szuhany KL; Department of Psychological and Brain Sciences, Boston University, Boston, Massachusetts.
Gueorguieva R; Department of Biostatistics, Yale University School of Public Health, New Haven, Connecticut.
Krystal JH; Department of Psychiatry, Yale University School of Medicine and Yale-New Haven Hospital, New Haven, Connecticut.
Simon NM; Center for Anxiety and Traumatic Stress Disorders, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Tolin DF; Institute of Living and Yale University School of Medicine, Hartford, Connecticut.
Pokaż więcej
Źródło:
Depression and anxiety [Depress Anxiety] 2016 Aug; Vol. 33 (8), pp. 737-45. Date of Electronic Publication: 2016 Jun 17.
Typ publikacji:
Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:
Antimetabolites/*pharmacology
Cognitive Behavioral Therapy/*methods
Cycloserine/*pharmacology
Panic Disorder/*therapy
Adult ; Combined Modality Therapy ; Double-Blind Method ; Female ; Humans ; Male ; Middle Aged ; Panic Disorder/drug therapy ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Translational Pharmacokinetic-Pharmacodynamic Modeling and Simulation: Optimizing 5-Fluorouracil Dosing in Children With Pediatric Ependymoma.
Autorzy:
Daryani VM; Department of Pharmaceutical Sciences St. Jude Children's Research Hospital Memphis Tennessee USA.
Patel YT; Department of Pharmaceutical Sciences St. Jude Children's Research Hospital Memphis Tennessee USA.
Tagen M; Genentech South San Francisco California USA.
Turner DC; Quantitative Pharmacology and Pharmacometrics Merck Research Laboratories Rahway New Jersey USA.
Carcaboso AM; Preclinical Therapeutics and Drug Delivery Research Program Hospital Sant Joan de Déu Barcelona Barcelona Spain.
Atkinson JM; Department of Pediatrics Pennsylvania State College of Medicine Hershey Pennsylvania USA.
Gajjar A; Department of Oncology St. Jude Children's Research Hospital Memphis Tennessee USA.
Gilbertson RJ; Cambridge Cancer Centre Cambridge UK.
Wright KD; Department of Oncology St. Jude Children's Research Hospital Memphis Tennessee USA.
Stewart CF; Department of Pharmaceutical Sciences St. Jude Children's Research Hospital Memphis Tennessee USA.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2016 Apr; Vol. 5 (4), pp. 211-221. Date of Electronic Publication: 2016 Apr 14.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Ependymoma/*drug therapy
Fluorouracil/*administration & dosage
Animals ; Antimetabolites, Antineoplastic/administration & dosage ; Antimetabolites, Antineoplastic/blood ; Antimetabolites, Antineoplastic/pharmacokinetics ; Blood Proteins/metabolism ; Child ; Child, Preschool ; Computer Simulation ; Drug Dosage Calculations ; Ependymoma/blood ; Ependymoma/metabolism ; Fluorouracil/blood ; Fluorouracil/pharmacokinetics ; Humans ; Mice ; Models, Biological ; Nonlinear Dynamics ; Protein Binding ; Random Allocation
SCR Disease Name:
Familial ependymoma
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Wyświetlanie 1-20 z 49

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies